Table 1.

Characteristics of included peanut oral immunotherapy studies.

Study/Year [Country]	RCT	Blinded OIT	Comparator	Co-Treatment	Entry OFC Type	Rush Phase	Peanut OIT Dose (mg peanut protein)		Exit OFC	Subjects Receiving OIT
							Starting	Target Maintenance
Anagnostou 2011 [UK]	No	No	None	None	DBPCFC	No	0.5	800	Open	22
Anagnostou 2014 [UK]	Yes	No	Peanut Avoidance	None	DBPCFC	No	2	800	DBPCFC	94
Bird 2015 [USA]	No	No	None	None	DBPCFC	No	Variable	2000	DBPCFC	11
Bird 2018 [USA]	Yes	Yes	Placebo	None	DBPCFC	Yes	0.5 to 6	300	DBPCFC	29
Blumchen 2010 [Germany]	No	No	None	None	DBPCFC	Yes	Variable	125	DBPCFC*	23
Blumchen 2019 [Germany]	Yes	Yes	Placebo	None	Open	No	Variable	125 or 250	Open	31
Fauquert 2018 [France]	Yes	Yes	Placebo	None	DBPCFC	No	2	400	DBPCFC	21
Hofmann 2009 [USA]	No	No	None	None	None	Yes	0.1 to 50	300	None	28
Howe 2019 [USA]	Yes	No	Symptoms as side effects (n = 24) or symptoms as positive signals (n = 26)	Antihistamine	None	No	1.3	240	None	50
Jones 2009 [USA]	No	No	None	None	None	Yes	0.1 to 50	300	Open	39
Kukkonen 2017 [Finland]	No	No	Peanut Avoidance	Antihistamine	DBPCFC	No	0.1	800	DBPCFC	39
MacGinnitie 2017 [USA]	Yes	No	Omalizumab + Oral OIT [n = 27] Vs. Oral OIT alone [n = 8]	Omalizumab	DBPCFC	Yes	0.5 to 250	2000	Open	35
Nachshon 2018 [Israel]	No	No	None	None	Open	Yes	Variable	1200 or 3000	Open	145
Nagakura 2018a [Japan]	No	No	None	Antihistamine & Montelukast	DBPCFC	Yes	Variable	795	OFC*	22
Nagakura 2018b [Japan]	No	No	None	Antihistamine	Open	Yes	Variable	133	OFC*	24
Narisety 2015 [USA]	Yes	No	Oral Vs. Sublingual OIT	None	Open	Yes	0.1 to 6	2000	Open	11
Nozawa 2014 [Japan]	No	No	None	None	DBPCFC	Yes	Variable	1750 or 3500	None	18
PALISADE 2018 [North America & Europe]	Yes	Yes	Placebo	None	DBPCFC	Yes	0.5 to 6	300	DBPCFC	372
Reier-Nilsen 2019 [Norway]	Yes	No	Peanut Avoidance	None	DBPCFC	No	5 or 1	5000	None	57
Schneider 2013 [USA]	No	No	None	Omalizumab	DBPCFC	Yes	0.05 to 250	4000	DBPCFC	13
Tang 2015 [Australia]	Yes	Yes	Placebo	Probiotic†	None	Yes	0.1 to 12	2000	DBPCFC	31
Tao 2017 [Australia]	No	No	None	None	Open	No	Boiled	2500	Open	14
Varshney 2011 [USA]	Yes	Yes	Placebo	None	None	Yes	0.1 to 6	4000	DBPCFC	19
Vickery 2017 [USA]	Yes	No	300 mg [n = 20] Vs. 3000 mg [17] maintenance dose	None	Open	Yes	0.05 to 3	300 vs. 3000	DBPCFC	37
Wasserman 2019 [USA]	No	No	None	None	None	Yes	0.001 to 10 mg/0.002 to 2.05 mg	3000	None	270
Yu 2012 [USA]	No	No	None	None	None	Yes	Variable	4000	None	24
Zhong 2019 [Singapore]	No	No	None	Probiotic†	Open	No	0.5	3000	Open	9

Abbreviations: RCT, randomised controlled trial; OIT, oral immunotherapy; OFC, oral food challenge; DBPCFC, double blind placebo controlled food challenge.

*OFC completed after 2 weeks of peanut avoidance.

^†Lactobacillus rhamnosus.